Novartis buys stem cell technology from Opexa Therapeutics

08/9/2009 | Reuters

Novartis purchased Opexa Therapeutics' preclinical-stage stem cell technology in a deal that could be worth more than $50 million. The sale allows Opexa to concentrate on the development and commercialization of multiple sclerosis drug Tovaxin, which is in midstage studies.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC